BRPI0809680A2 - Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de lxr alfa e/ou lxr beta e uso dos compostos. - Google Patents

Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de lxr alfa e/ou lxr beta e uso dos compostos.

Info

Publication number: BRPI0809680A2
Authority: BR; Brazil
Prior art keywords: compounds; lxr; modulated; therapeutic; manufacture
Prior art date: 2007-03-30

Application number

BRPI0809680-5A2A

Other languages

English (en)

Inventor

Henrietta Dehmlow

Ulrike Obst Sander

Stephan Roever

Bernd Kuhn

Tanja Schulz-Gasch

Matthew Wright

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-03-30

Filing date

2008-03-18

Publication date

2014-10-07

2008-03-18 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2014-10-07 Publication of BRPI0809680A2 publication Critical patent/BRPI0809680A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Obesity (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Virology (AREA)
Dermatology (AREA)
Biomedical Technology (AREA)
Tropical Medicine & Parasitology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
AIDS & HIV (AREA)
Psychiatry (AREA)
Molecular Biology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)

BRPI0809680-5A2A 2007-03-30 2008-03-18 Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de lxr alfa e/ou lxr beta e uso dos compostos. BRPI0809680A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP07105376		2007-03-30
PCT/EP2008/053192 WO2008119657A1 (en)	2007-03-30	2008-03-18	Imidazolidinone derivatives

Publications (1)

Publication Number	Publication Date
BRPI0809680A2 true BRPI0809680A2 (pt)	2014-10-07

Family

ID=39661434

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0809680-5A2A BRPI0809680A2 (pt)	2007-03-30	2008-03-18	Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de lxr alfa e/ou lxr beta e uso dos compostos.

Country Status (22)

Country	Link
US (1)	US7625902B2 (pt)
EP (1)	EP2142533B1 (pt)
JP (1)	JP5165748B2 (pt)
KR (1)	KR101171433B1 (pt)
CN (1)	CN101641348B (pt)
AR (1)	AR065863A1 (pt)
AT (1)	ATE533761T1 (pt)
AU (1)	AU2008234017B2 (pt)
BR (1)	BRPI0809680A2 (pt)
CA (1)	CA2681809C (pt)
CL (1)	CL2008000875A1 (pt)
DK (1)	DK2142533T3 (pt)
ES (1)	ES2375586T3 (pt)
IL (1)	IL200868A0 (pt)
MX (1)	MX2009010567A (pt)
PE (1)	PE20090549A1 (pt)
PL (1)	PL2142533T3 (pt)
PT (1)	PT2142533E (pt)
RU (1)	RU2437882C2 (pt)
TW (1)	TWI348908B (pt)
WO (1)	WO2008119657A1 (pt)
ZA (1)	ZA200906467B (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2008288537B2 (en) *	2007-08-13	2011-03-24	F. Hoffmann-La Roche Ag	Novel piperazine amide derivatives
EP2242745A1 (de) *	2008-02-07	2010-10-27	Sanofi-Aventis	Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2011157827A1 (de)	2010-06-18	2011-12-22	Sanofi	Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
AU2011299703A1 (en)	2010-09-07	2013-04-11	Snu R&Db Foundation	Sesterterpene compounds and use thereof
WO2014164767A1 (en)	2013-03-13	2014-10-09	Forma Therapeutics, Inc.	Novel compounds and compositions for inhibition of fasn
TWI744242B (zh)	2015-07-31	2021-11-01	德商安美基研究（慕尼黑）公司	Egfrviii及cd3抗體構築體
EA039859B1 (ru)	2015-07-31	2022-03-21	Эмджен Рисерч (Мюник) Гмбх	Биспецифические конструкты антител, связывающие egfrviii и cd3
US10239849B2 (en)	2015-11-12	2019-03-26	Merck Sharp & Dohme Corp.	Cyanopyridine derivatives as liver X receptor beta agonists, compositions, and their use
CA3011942A1 (en)	2016-02-03	2017-08-10	Amgen Research (Munich) Gmbh	Psma and cd3 bispecific t cell engaging antibody constructs
US11236053B2 (en)	2017-07-26	2022-02-01	Emory University	NADPH oxidase inhibitors and uses thereof
US11136290B2 (en)	2018-05-22	2021-10-05	The Liver Company Inc.	Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
TWI748194B (zh)	2018-06-28	2021-12-01	德商菲尼克斯Ｆｘｒ有限責任公司	含有雙環核心部分之新穎lxr調節劑
TWI767148B (zh)	2018-10-10	2022-06-11	美商弗瑪治療公司	抑制脂肪酸合成酶(fasn)
US10793554B2 (en)	2018-10-29	2020-10-06	Forma Therapeutics, Inc.	Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US20230069886A1 (en) *	2020-01-10	2023-03-09	Uniwersytet Jagiellonski	Aromatic sulphonamides derivatives that inhibits pdi a3, their synthesis and use
EP4087651A1 (en) *	2020-01-10	2022-11-16	Uniwersytet Jagiellonski	Aromatic sulphonamides derivatives that inhibits pdi a1, their synthesis and use
US20250146017A1 (en)	2023-11-06	2025-05-08	City Of Hope	Methods comprising oncolytic viruses expressing cd19t and bispecific t cell engagers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0966462B1 (en) *	1997-02-13	2003-06-11	AstraZeneca AB	Heterocyclic compounds useful as oxido-squalene cyclase inhibitors
US6316503B1 (en) *	1999-03-15	2001-11-13	Tularik Inc.	LXR modulators
FR2802206B1 (fr) *	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
AU2000235960A1 (en) *	2000-02-14	2001-08-27	Tularik, Inc.	Lxr modulators
AU2001234175B2 (en) *	2000-02-29	2004-10-07	Mitsubishi Pharma Corporation	Novel cyclic amide derivatives
EP1318976B1 (en) *	2000-09-18	2004-11-24	Glaxo Group Limited	Substituted aminopropoxyaryl derivatives useful as agonists for lxr
EP1509495A1 (en)	2002-05-24	2005-03-02	Pharmacia Corporation	Anilino liver x-receptor modulators
WO2005040109A1 (en) *	2003-10-22	2005-05-06	Neurocrine Biosciences, Inc.	Ligands of melanocortin receptors and compositions and methods related thereto
MXPA06014573A (es) *	2004-06-24	2007-03-12	Incyte Corp	Compuestos amido y su uso como farmaceuticos.
RU2389718C2 (ru)	2004-06-28	2010-05-20	Ф.Хоффманн-Ля Рош Аг	Новые производные гексафторизопропанола
DE102005000666B3 (de) *	2005-01-04	2006-10-05	Sanofi-Aventis Deutschland Gmbh	Sulfonylpyrrolidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel

2008
- 2008-03-18 WO PCT/EP2008/053192 patent/WO2008119657A1/en not_active Ceased
- 2008-03-18 CA CA2681809A patent/CA2681809C/en not_active Expired - Fee Related
- 2008-03-18 CN CN200880009826.7A patent/CN101641348B/zh not_active Expired - Fee Related
- 2008-03-18 AU AU2008234017A patent/AU2008234017B2/en not_active Ceased
- 2008-03-18 DK DK08717926.3T patent/DK2142533T3/da active
- 2008-03-18 ES ES08717926T patent/ES2375586T3/es active Active
- 2008-03-18 EP EP08717926A patent/EP2142533B1/en not_active Not-in-force
- 2008-03-18 RU RU2009139915/04A patent/RU2437882C2/ru not_active IP Right Cessation
- 2008-03-18 KR KR1020097022619A patent/KR101171433B1/ko not_active Expired - Fee Related
- 2008-03-18 PT PT08717926T patent/PT2142533E/pt unknown
- 2008-03-18 BR BRPI0809680-5A2A patent/BRPI0809680A2/pt not_active IP Right Cessation
- 2008-03-18 PL PL08717926T patent/PL2142533T3/pl unknown
- 2008-03-18 JP JP2010501464A patent/JP5165748B2/ja not_active Expired - Fee Related
- 2008-03-18 MX MX2009010567A patent/MX2009010567A/es active IP Right Grant
- 2008-03-18 AT AT08717926T patent/ATE533761T1/de active
- 2008-03-24 US US12/053,674 patent/US7625902B2/en not_active Expired - Fee Related
- 2008-03-27 CL CL200800875A patent/CL2008000875A1/es unknown
- 2008-03-27 AR ARP080101267A patent/AR065863A1/es not_active Application Discontinuation
- 2008-03-27 TW TW097111130A patent/TWI348908B/zh not_active IP Right Cessation
- 2008-03-27 PE PE2008000551A patent/PE20090549A1/es not_active Application Discontinuation
2009
- 2009-09-10 IL IL200868A patent/IL200868A0/en unknown
- 2009-09-16 ZA ZA200906467A patent/ZA200906467B/xx unknown

Also Published As

Publication number	Publication date
RU2437882C2 (ru)	2011-12-27
CN101641348B (zh)	2014-09-10
PL2142533T3 (pl)	2012-04-30
TWI348908B (en)	2011-09-21
KR20090130090A (ko)	2009-12-17
JP5165748B2 (ja)	2013-03-21
JP2010523514A (ja)	2010-07-15
EP2142533B1 (en)	2011-11-16
PE20090549A1 (es)	2009-05-09
CA2681809C (en)	2012-06-05
RU2009139915A (ru)	2011-05-10
WO2008119657A1 (en)	2008-10-09
ATE533761T1 (de)	2011-12-15
AU2008234017A1 (en)	2008-10-09
EP2142533A1 (en)	2010-01-13
KR101171433B1 (ko)	2012-08-06
ZA200906467B (en)	2010-05-26
DK2142533T3 (da)	2011-12-12
US20080242677A1 (en)	2008-10-02
AR065863A1 (es)	2009-07-08
AU2008234017B2 (en)	2011-09-22
TW200848046A (en)	2008-12-16
CA2681809A1 (en)	2008-10-09
ES2375586T3 (es)	2012-03-02
CL2008000875A1 (es)	2008-10-03
PT2142533E (pt)	2012-01-19
US7625902B2 (en)	2009-12-01
MX2009010567A (es)	2009-10-22
IL200868A0 (en)	2010-05-17
CN101641348A (zh)	2010-02-03

Similar Documents

Publication	Publication Date	Title
BRPI0809680A2 (pt)	2014-10-07	Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por agonistas de lxr alfa e/ou lxr beta e uso dos compostos.
BRPI0820622A2 (pt)	2015-06-16	Compostos derivados de aminotiazol, processo para a sua preparação, composição farmacêutica que os compreende, uso dos mesmos e métodos para o tratamento e/ou profilaxia de diabetes e outras enfermidades
BRPI0821299A2 (pt)	2015-06-16	Composto, processo para preparar o mesmo, composição farmacêutica, processo para preparar a mesma, uso de um composto, e, método para tratar, ou reduzir o risco de, uma doença ou condição.
BRPI0906786A2 (pt)	2015-07-14	Composto, processo para a preparação de um composto, uso de um composto, método para o tratamento de uma doença ou condição, composição farmacêutica, processo para a preparação de uma composição farmacêutica, produto, e, kit.
BRPI0915084A2 (pt)	2015-10-27	composto, processo para a preparação de um composto, composição farmacêutica, uso de um composto, métodos para a profilaxia ou tratamento de um estado de doença ou uma condição e de câncer
BRPI0919057A2 (pt)	2018-01-09	compostos de indazol ou derivados, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento ou profilaxia de enfermidades que são afetadas por moduladores de fxr, e uso dos compostos
BRPI0817242A2 (pt)	2015-06-16	Composto derivado de 1,1,1-trifluoro -2-hidroxi-3-fenilpropano, processo para a sua manufatura, composição farmacêuticas que os contêm, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de glicocorticóides e uso de tais compostos
BRPI0819755A2 (pt)	2018-07-17	composto, composição farmacêutica, processos para a preparação de um composto e de uma composição farmacêutica, uso de um composto, e, método para tratar ou reduzir o risco de uma doença ou uma condição inflamatória
BRPI0820203A2 (pt)	2015-06-16	Compostos de pirrdina, processo para a sua preparação, composição farmacêutica que os compreende, uso de composto e método para o tratamento e/ou profilaxia de diabetes mellitus do tipo ii e outras enfermidades
BRPI1013396A2 (pt)	2016-03-29	composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BRPI0712631B8 (pt)	2021-05-25	compostos, processos para a preparação de um composto, composição farmacêutica, uso de um composto e combinações
BRPI0915862A2 (pt)	2015-11-03	compostos derivados de tetraidrocinolina, processo para sua fabricação, composição farmacêutica que os compreende, uso dos mesmos e método para o tratamento ou profilaxia de diabetes e outras enfermidades
BRPI0818533A2 (pt)	2017-06-06	composto, composição farmacêutica, e, processo para a preparação de um composto
BRPI0718587A2 (pt)	2014-03-11	Uso de um composto, compostos, método de tratamento ou prevenção de doenças, processos para a preparação do composto e composição farmacêutica contendo o mesmo
BRPI0816881A2 (pt)	2015-03-17	Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BRPI0909768A2 (pt)	2015-10-06	composto, composição farmacêutica, método para o tratamento ou prevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto""composto, composição farmacêutica, método para o tratamento ou orevenção de uma doença ou distúrbio mediados pela ativação de b3-adrenoceptor, e, uso de um composto
BRPI0816553A2 (pt)	2017-07-18	"composto, composição farmcêutica, uso de uma composição, uso de um composto, e, processo para a preparação de um composto"
BRPI0717822A2 (pt)	2013-11-12	Composto, processo de fabricação de composto da fórmula i, composição farmacêutica, método de tratamento e/ou profilaxia de doenças que são associadas à modulação de receptores de cb2 e uso de composto.
BRPI0815591A2 (pt)	2015-03-03	Composto, composição farmacêutica, uso de um composto, e, método para tratar uma doença, condição ou distúrbio.
BRPI0918809A2 (pt)	2015-12-01	compostos derivados de benzimidazol, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento terapêutico e/ou profilático de enfermidades que são afetadas por moduladores de fxr e uso dos compostos
BRPI0816331A2 (pt)	2015-04-14	Composto, uso de um composto, composição farmacêutica, e, processo para preparar um composto.
BRPI0912539A2 (pt)	2015-10-13	composto, composição farmacêutica , método para tratar uma doença, e, uso do composto.
BRPI0716535A2 (pt)	2013-09-24	compostos, processo para sua manufatura, composiÇÕes farmacÊuticas que os compreendem, mÉtodo para o tratamento e/ou profilaxia de enfermidades que estço associadas com a modulaÇço de receptores de cb1 e utilizaÇço dos compostos
BRPI0816814A2 (pt)	2017-05-16	composto, composição farmacêutica, método para tratar, prevenir ou melhorar uma doença mediada por gsk-3, uso de um composto, e, artigo de fabricação.
BRPI0913597A2 (pt)	2015-11-24	compostos derivados de imidazolidina, processo para a sua manufatura, método para o tratamento terapêutico e/ou profilático de enfermidades que são moduladas por lxr alfa e/ou lxr beta e uso destes compostos

Legal Events

Date	Code	Title	Description
2017-01-17	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2017-05-23	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]